Gastaca M
Hepato-biliary Surgery and Liver Transplantation Unit, Hospital de Cruces, Bilbao, Spain.
Transplant Proc. 2009 Apr;41(3):975-9. doi: 10.1016/j.transproceed.2009.02.016.
Despite the progressive increase in the number of liver transplantations, the mortality on the waiting list remains between 5% and 10%, and patients have to deal with longer waiting periods. Facing this situation, transplant centers have developed alternatives to increase the number of grafts by accepting donors who were previously considered to be inadequate, because they are at higher risk of initial poor function and graft failure or may cause disease transmission. Currently, some marginal donors are being routinely used: elderly donors, steatotic grafts, non-heart-beating donors, hepatitis C virus-positive (HCV+) or hepatitis B core antibody-positive donors. These so-called marginal or extended-criteria donors were initially used in high-risk or urgent recipients; however, the number of marginal grafts has significantly increased, forcing the transplant community toward their more rationale use to maintain excellent results of liver transplantation. In this new scenario, the adequacy between donor and recipient may be paramount. Advanced donor age seems to be related to a greater graft failure rate in HCV+ recipients. Early survival seems to be significantly reduced when steatotic grafts are used in recipients with high Model for End-stage Liver Disease (MELD) scores. Moreover, a decreased survival has been observed among high-risk patients receiving organs from marginal donors. No benefit seems to exist when high-donor risk index grafts are transplanted into recipients with low MELD Scores. The recognition of various donor groups according to their quality and the need for good donor and recipient selection must lead us to define new policies for organ allocation of marginal grafts that may come into conflict with current policies of organ allocation according to the risk of death among patients awaiting a liver transplantation.
尽管肝移植数量在逐步增加,但等待名单上的死亡率仍在5%至10%之间,患者不得不面对更长的等待期。面对这种情况,移植中心已开发出替代方案,通过接受以前被认为不合适的供体来增加移植物数量,因为这些供体初始功能不良和移植物失败的风险更高,或者可能导致疾病传播。目前,一些边缘供体正在被常规使用:老年供体、脂肪变性移植物、非心脏跳动供体、丙型肝炎病毒阳性(HCV+)或乙肝核心抗体阳性供体。这些所谓的边缘或扩展标准供体最初用于高风险或紧急受者;然而,边缘移植物的数量已显著增加,这迫使移植界更合理地使用它们,以保持肝移植的优异效果。在这种新情况下,供体与受体之间的匹配可能至关重要。供体年龄较大似乎与HCV+受者中更高的移植物失败率相关。当在终末期肝病模型(MELD)评分高的受者中使用脂肪变性移植物时,早期存活率似乎会显著降低。此外,在接受边缘供体器官的高风险患者中观察到存活率下降。当将高供体风险指数移植物移植到MELD评分低的受者中时,似乎没有益处。根据供体质量识别不同的供体群体以及良好的供体和受体选择的必要性,必须促使我们为边缘移植物的器官分配定义新政策,这可能与当前根据等待肝移植患者的死亡风险进行器官分配的政策相冲突。